Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380968 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TDP1TSHRCYP19A1CYP3A4 | |
| SCHEMBL219410 | 0.84 | CYP19A1 (0.55) | ALDH1A1TSHRCYP19A1CYP3A4ACP1 | |
| SCHEMBL204235 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TDP1TSHRCYP19A1CYP3A4 | |
| SCHEMBL1026447 | 0.84 | CYP19A1 (0.62) | ALDH1A1TSHRCYP19A1CYP3A4ACP1 | |
| SCHEMBL1943699 | 0.84 | CYP19A1 (0.62) | ALDH1A1TDP1TSHRCYP19A1CYP3A4 | |
| Chlorobenzene SCHEMBL27337913 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TDP1TSHRCYP19A1HSD17B10 | |
| Benzene SCHEMBL27733872 | 0.79 | ALDH1A1 (0.61) | ALDH1A1TDP1TSHRCYP19A1CYP3A4 | |
| Nitrogen SCHEMBL9840130 | 0.79 | CYP19A1 (0.56) | ALDH1A1TDP1TSHRCYP19A1CYP3A4 | |
| Nitrogen SCHEMBL27917117 | 0.79 | CYP19A1 (0.56) | ALDH1A1TSHRCYP19A1CYP3A4ACP1 | |
| Benzene SCHEMBL27782128 | 0.79 | CYP19A1 (0.56) | ALDH1A1TSHRCYP19A1CYP3A4ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105218379-A | The synthetic method of the chloro-5-bromaniline of a kind of 3- | GAO DAYUAN | 2016-01-06 | — | — | CN | claimed |
| US-20130122599-A1 | Fragmentation Reagents For Mass Spectrometry | MICROMASS UK LIMITED (GB) | 2013-05-16 | — | — | US | claimed |
| EP-2529388-A1 | FRAGMENTATION REAGENTS FOR MASS SPECTROMETRY | Micromass UK Limited (GB) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092515-A1 | FRAGMENTATION REAGENTS FOR MASS SPECTROMETRY | MICROMASS UK LIMITED (GB) | 2011-08-04 | — | — | WO | claimed |
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | TOLREMO THERAPEUTICS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | TOLREMO THERAPEUTICS AG (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3227271-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-08-12 | — | — | US | disclosed |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TOLREMO THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025011623-A1 | CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-7666891-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2121600-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| CN-1227299-C | Azo-type disperse dyes for dyeing in acid-alkaline baths | HUAMAO FINE CHEMICAL CO LTD PE (CN) | 2005-11-16 | — | — | CN | disclosed |
| CN-1563204-A | Azo-type disperse dyes for dyeing in acid-alkaline baths | HUAMAO FINE CHEMICAL CO LTD PE (CN) | 2005-01-12 | — | — | CN | disclosed |
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| WO-1999001442-A1 | TRIAZINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472179-B2 | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer | EP300, KRAS, BRD4 | ALDH1A1 2352/4885TDP1 3289/4885TSHR 3259/4885 |
| US-12595258-B2 | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer | SLC10A1, MAPT, SLC6A6 | ALDH1A1 1234/4885TDP1 763/4885TSHR 3591/4885 |
| US-12383624-B2 | Cargo delivery system and composition comprising the same | ATG7, SQSTM1, BECN1 | ALDH1A1 4664/4885TDP1 3713/4885TSHR 3779/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | ALDH1A1 3953/4885TDP1 3081/4885TSHR 4516/4885 |
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | ALDH1A1 1144/4885TDP1 2443/4885TSHR 479/4885 |
| US-20250243191-A1 | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER | TP53, MAPT, SLC10A1 | ALDH1A1 1003/4885TDP1 751/4885TSHR 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.